BC Innovations | Feb 7, 2013
Cover Story

2012 gets a new deal

SciBX 's second annual comprehensive analysis of public-private partnerships and early stage venture financing activity reveals that government institutions and organizations are taking a significant role in forming and funding partnerships, and California-based companies are...
BioCentury | Oct 15, 2012
Finance

Banker tracks

Banker tracks IT services and tech investment banking firm WWC Securities has changed its name to Outcome Capital and added a life sciences practice. WWC will offer advisory services and investment banking to private biotechs...
BioCentury | Aug 6, 2012
Finance

Histogenics regeneration

Histogenics regeneration Sofinnova Ventures made its first regenerative medicine investment last month when it led a $49 million round that recapped Histogenics Corp. New investors Split Rock Partners; BioMed Ventures; and FinTech GIMV Fund participated...
BC Week In Review | Jul 30, 2012
Financial News

Histogenics completes venture financing

Histogenics Corp. , Waltham, Mass.   Business: Musculoskeletal   Date completed: 7/24/12   Type: Venture financing   Raised: $49 million   Investors: Sofinnova Ventures; Split Rock Partners; BioMed Venture; FinTech GIMV Fund; ProChon Holdings; Altima Partners;...
BC Extra | Jul 25, 2012
Financial News

Histogenics raises $49M in series A

Histogenics Corp. (Waltham, Mass.) raised $49 million in a series A round led by new investor Sofinnova Ventures. New investors Split Rock Partners; BioMed Ventures; and FinTech GIMV Fund participated along with existing investors ProChon...
BC Week In Review | May 23, 2011
Company News

Histogenics, ProChon Biotech deal

Histogenics acquired ProChon, a developer of fibroblast growth factor-based therapeutics, in a stock-for-stock merger. ProChon CEO Patrick O'Donnell was named CEO, president and a director of the combined company. Histogenics plans to use ProChon's Fibroblast...
BC Week In Review | Jun 21, 2010
Company News

ProChon Biotech management update

ProChon Biotech Ltd. , Woburn, Mass.   Business: Musculoskeletal   Hired: Brian Callahan as EVP of regulatory and quality affairs, founder and former principal of EEC & Associates  ...
BC Week In Review | Jan 25, 2010
Financial News

ProChon Biotech completes venture financing

ProChon Biotech Ltd. , Woburn, Mass.   Business: Musculoskeletal   Date completed: 1/20/10   Type: Venture financing   Raised: $4 million   Investors: ProChon Holdings B.V.; Musculoskeletal Transplant Foundation   Note: The offering is a convertible...
BC Week In Review | Dec 11, 2006
Company News

ProChon Biotech, Semafore, Multiple Myeloma Research Foundation cancer news

The foundation awarded $1 million grants to Semafore and ProChon. The grants will be used to develop Semafore's SF1126 , a phosphoinositide 3-kinase (PI3K) inhibitor, and ProChon's PRO-001, an antibody against fibroblast growth factor (FGF) receptor...
BC Week In Review | Apr 18, 2005
Company News

ProChon Biotech, Musculoskeletal Transplant Foundation deal

The foundation will fund ProChon's research on combining ProChon's factors and cell technologies with the foundation's allograft and tissue materials. The foundation will be responsible for preclinical and clinical development and will have exclusive worldwide...
Items per page:
1 - 10 of 17
BC Innovations | Feb 7, 2013
Cover Story

2012 gets a new deal

SciBX 's second annual comprehensive analysis of public-private partnerships and early stage venture financing activity reveals that government institutions and organizations are taking a significant role in forming and funding partnerships, and California-based companies are...
BioCentury | Oct 15, 2012
Finance

Banker tracks

Banker tracks IT services and tech investment banking firm WWC Securities has changed its name to Outcome Capital and added a life sciences practice. WWC will offer advisory services and investment banking to private biotechs...
BioCentury | Aug 6, 2012
Finance

Histogenics regeneration

Histogenics regeneration Sofinnova Ventures made its first regenerative medicine investment last month when it led a $49 million round that recapped Histogenics Corp. New investors Split Rock Partners; BioMed Ventures; and FinTech GIMV Fund participated...
BC Week In Review | Jul 30, 2012
Financial News

Histogenics completes venture financing

Histogenics Corp. , Waltham, Mass.   Business: Musculoskeletal   Date completed: 7/24/12   Type: Venture financing   Raised: $49 million   Investors: Sofinnova Ventures; Split Rock Partners; BioMed Venture; FinTech GIMV Fund; ProChon Holdings; Altima Partners;...
BC Extra | Jul 25, 2012
Financial News

Histogenics raises $49M in series A

Histogenics Corp. (Waltham, Mass.) raised $49 million in a series A round led by new investor Sofinnova Ventures. New investors Split Rock Partners; BioMed Ventures; and FinTech GIMV Fund participated along with existing investors ProChon...
BC Week In Review | May 23, 2011
Company News

Histogenics, ProChon Biotech deal

Histogenics acquired ProChon, a developer of fibroblast growth factor-based therapeutics, in a stock-for-stock merger. ProChon CEO Patrick O'Donnell was named CEO, president and a director of the combined company. Histogenics plans to use ProChon's Fibroblast...
BC Week In Review | Jun 21, 2010
Company News

ProChon Biotech management update

ProChon Biotech Ltd. , Woburn, Mass.   Business: Musculoskeletal   Hired: Brian Callahan as EVP of regulatory and quality affairs, founder and former principal of EEC & Associates  ...
BC Week In Review | Jan 25, 2010
Financial News

ProChon Biotech completes venture financing

ProChon Biotech Ltd. , Woburn, Mass.   Business: Musculoskeletal   Date completed: 1/20/10   Type: Venture financing   Raised: $4 million   Investors: ProChon Holdings B.V.; Musculoskeletal Transplant Foundation   Note: The offering is a convertible...
BC Week In Review | Dec 11, 2006
Company News

ProChon Biotech, Semafore, Multiple Myeloma Research Foundation cancer news

The foundation awarded $1 million grants to Semafore and ProChon. The grants will be used to develop Semafore's SF1126 , a phosphoinositide 3-kinase (PI3K) inhibitor, and ProChon's PRO-001, an antibody against fibroblast growth factor (FGF) receptor...
BC Week In Review | Apr 18, 2005
Company News

ProChon Biotech, Musculoskeletal Transplant Foundation deal

The foundation will fund ProChon's research on combining ProChon's factors and cell technologies with the foundation's allograft and tissue materials. The foundation will be responsible for preclinical and clinical development and will have exclusive worldwide...
Items per page:
1 - 10 of 17